[go: up one dir, main page]

WO2019203759A3 - Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation - Google Patents

Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation Download PDF

Info

Publication number
WO2019203759A3
WO2019203759A3 PCT/TR2019/050005 TR2019050005W WO2019203759A3 WO 2019203759 A3 WO2019203759 A3 WO 2019203759A3 TR 2019050005 W TR2019050005 W TR 2019050005W WO 2019203759 A3 WO2019203759 A3 WO 2019203759A3
Authority
WO
WIPO (PCT)
Prior art keywords
etodolac
pharmaceutically acceptable
inflammation
pain
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050005
Other languages
English (en)
Other versions
WO2019203759A2 (fr
Inventor
Mehmet Nevzat PISAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2019203759A2 publication Critical patent/WO2019203759A2/fr
Publication of WO2019203759A3 publication Critical patent/WO2019203759A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale stable à libération immédiate sous une forme posologique unitaire comprenant de l'étodolac ou un sel pharmaceutiquement acceptable de celui-ci, de la famotidine ou un sel pharmaceutiquement acceptable de celle-ci et un excipient pharmaceutiquement acceptable. La présente invention concerne en outre des formulations pharmaceutiques d'étodolac et de famotidine présentant une stabilité et un profil de dissolution améliorés tout en réduisant les effets secondaires gastro-intestinaux.
PCT/TR2019/050005 2018-01-03 2019-01-03 Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation Ceased WO2019203759A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TRPCT/TR2018/050003 2018-01-03
PCT/TR2018/050003 WO2019135725A1 (fr) 2018-01-03 2018-01-03 Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation

Publications (2)

Publication Number Publication Date
WO2019203759A2 WO2019203759A2 (fr) 2019-10-24
WO2019203759A3 true WO2019203759A3 (fr) 2020-01-23

Family

ID=64559738

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2018/050003 Ceased WO2019135725A1 (fr) 2018-01-03 2018-01-03 Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation
PCT/TR2019/050005 Ceased WO2019203759A2 (fr) 2018-01-03 2019-01-03 Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050003 Ceased WO2019135725A1 (fr) 2018-01-03 2018-01-03 Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation

Country Status (1)

Country Link
WO (2) WO2019135725A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699380A (zh) * 2021-12-27 2022-07-05 南京联智医药科技有限公司 一种依托度酸片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
WO2012173581A1 (fr) * 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Combinaisons de thiocolchicoside, étodolac et famotidine
WO2013169218A1 (fr) * 2012-05-08 2013-11-14 Mahmut Bilgic Compositions pharmaceutiques de s-étodolac

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ATE474559T1 (de) 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
AU2005213472A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20090233970A1 (en) 2008-03-11 2009-09-17 Nickell Robert P Combined nsaid and acid blocker formulation and method
TWI564008B (zh) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
WO2014007777A1 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations combinées de ains sous forme de gélule
US20150182457A1 (en) 2013-12-31 2015-07-02 Ascendia Pharmaceuticals, Llc Pharmaceutical Compositions For Poorly Water-Soluble Compounds
WO2018004498A1 (fr) * 2016-06-30 2018-01-04 Imuneks Farma Ilac San. Ve Tic. A.S. Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
WO2012173581A1 (fr) * 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Combinaisons de thiocolchicoside, étodolac et famotidine
WO2013169218A1 (fr) * 2012-05-08 2013-11-14 Mahmut Bilgic Compositions pharmaceutiques de s-étodolac

Also Published As

Publication number Publication date
WO2019203759A2 (fr) 2019-10-24
WO2019135725A1 (fr) 2019-07-11

Similar Documents

Publication Publication Date Title
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
NZ605469A (en) Nalbuphine-based formulations and uses thereof
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
PH12014502331A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
EP4609912A3 (fr) Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
TN2015000135A1 (en) Modified release formulations for oprozomib
MY206893A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2023012198A (es) Composiciones de amantadina, preparaciones de estas y metodos de uso.
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2019203759A3 (fr) Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
WO2020013776A3 (fr) Effet synergique du naproxène et un agent protecteur gatrique qui traite la douleur et l'inflammation
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
WO2020032883A3 (fr) Effets synergiques d'une nouvelle formulation de kétoprofène comprenant un agent gastro-protecteur
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2018231176A3 (fr) Combinaisons de diclofénac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
MX2017014725A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19769255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM DATED 30.09.2020)

122 Ep: pct application non-entry in european phase

Ref document number: 19769255

Country of ref document: EP

Kind code of ref document: A2